Journal of Thrombosis and Thrombolysis

, Volume 28, Issue 3, pp 299–303

Expression of adhesion factor CD239 in bone marrow cells in chronic myeloproliferative diseases

  • Kais Hussein
  • Katharina Theophile
  • Katrin Denzer
  • Hans Kreipe
  • Oliver Bock
Article
  • 92 Downloads

Abstract

Patients suffering from Philadelphia chromosome-negative chronic myeloproliferative disease (Ph CMPD), such as polycythaemia vera (PV), are frequently JAK2V617F-mutated and have an elevated risk for thromboembolic complications. Recent data indicated that the molecular basis of JAK2V617F and thrombosis might be related to increased expression of CD239, the Lutheran blood group/basal cell adhesion molecule, in PV-derived red blood cells. The aim of this study was to clarify whether JAK2V617F PV with thromboembolism is characterised by CD239 overexpression. Leukocyte-derived JAK2V617F was detectable in bone marrow cells but also in liver and spleen explants and transplants after thrombosis (95% JAK2V617F-positive Ph CMPD, n = 66). CD239 was expressed in a constitutive fashion in PV-derived bone marrow cells and thus a pro-thrombotic function does not seem to be mediated by increased CD239 expression alone.

Keywords

Thrombosis CD239 Lutheran blood group/basal cell adhesion molecule Philadelphia chromosome-negative myeloproliferative disease JAK2V617F 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Kais Hussein
    • 1
  • Katharina Theophile
    • 1
  • Katrin Denzer
    • 1
  • Hans Kreipe
    • 1
  • Oliver Bock
    • 1
  1. 1.Institute of PathologyHannover Medical SchoolHannoverGermany

Personalised recommendations